OncoMatch/Clinical Trials/NCT01804634
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Is NCT01804634 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cyclophosphamide and Fludarabine for refractory and/or relapsed metastatic solid tumors.
Treatment: Cyclophosphamide · Fludarabine · Melphalan · Tacrolimus — The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Required: Stage IV, STAGE 4
Metastatic disease required
Patients must have a confirmed histopathologic diagnosis and be classified as high risk defined by having an expected survival of < 10%
Performance status
KARNOFSKY/LANSKY 60–100
Prior therapy
Must have received: standard of care therapy — upfront
It is expected that patients will have received upfront standard of care therapy for their respected disease
Must have received: autologous bone marrow transplant — relapsed after single or tandem autologous BMT
Patients who relapse after either single or tandem autologous BMT are eligible (> 6 months must have elapsed from start of last BMT)
Lab requirements
Kidney function
serum creatinine within normal range for age, or if serum creatinine outside normal range for age, then renal function (creatinine clearance or gfr) > 40 ml/min/1.73m2
Liver function
bilirubin ≤ 3.0 mg/dl; and alt, ast, and alkaline phosphatase < 5 x uln
Cardiac function
left ventricular ejection fraction at rest must be ≥ 35%, or shortening fraction > 25%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland
- Albert Einstein College of Medicine, Children's Hospital at Montefiore · The Bronx, New York
- New York Medical Center/ Maria Fareri Children's Hospital · Valhalla, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify